vs
Side-by-side financial comparison of Gloo Holdings, Inc. (GLOO) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
Gloo Holdings, Inc. is the larger business by last-quarter revenue ($32.6M vs $19.1M, roughly 1.7× NewAmsterdam Pharma Co N.V.). NewAmsterdam Pharma Co N.V. runs the higher net margin — -90.7% vs -116.9%, a 26.2% gap on every dollar of revenue. NewAmsterdam Pharma Co N.V. produced more free cash flow last quarter ($-37.8M vs $-63.4M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
GLOO vs NAMS — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.6M | $19.1M |
| Net Profit | $-38.0M | $-17.4M |
| Gross Margin | — | — |
| Operating Margin | -82.0% | -186.1% |
| Net Margin | -116.9% | -90.7% |
| Revenue YoY | — | 740.1% |
| Net Profit YoY | 12.2% | 55.5% |
| EPS (diluted) | $-6.08 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $32.6M | — | ||
| Q2 25 | — | $19.1M | ||
| Q4 24 | — | $12.8M | ||
| Q3 24 | — | $29.1M | ||
| Q2 23 | — | $8.6M |
| Q4 25 | $-38.0M | — | ||
| Q2 25 | — | $-17.4M | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | — | $-16.6M | ||
| Q2 23 | — | $-42.0M |
| Q4 25 | -82.0% | — | ||
| Q2 25 | — | -186.1% | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | — | -85.9% | ||
| Q2 23 | — | -461.8% |
| Q4 25 | -116.9% | — | ||
| Q2 25 | — | -90.7% | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | — | -57.2% | ||
| Q2 23 | — | -486.9% |
| Q4 25 | $-6.08 | — | ||
| Q2 25 | — | $-0.15 | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 23 | — | $-0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.1M | $739.2M |
| Total DebtLower is stronger | $176.5M | — |
| Stockholders' EquityBook value | $-444.4M | $778.5M |
| Total Assets | $206.7M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.1M | — | ||
| Q2 25 | — | $739.2M | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q2 23 | — | — |
| Q4 25 | $176.5M | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | $-444.4M | — | ||
| Q2 25 | — | $778.5M | ||
| Q4 24 | — | $757.5M | ||
| Q3 24 | — | $378.9M | ||
| Q2 23 | — | $398.4M |
| Q4 25 | $206.7M | — | ||
| Q2 25 | — | $815.1M | ||
| Q4 24 | — | $864.6M | ||
| Q3 24 | — | $439.2M | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.0M | $-37.7M |
| Free Cash FlowOCF − Capex | $-63.4M | $-37.8M |
| FCF MarginFCF / Revenue | -194.8% | -197.2% |
| Capex IntensityCapex / Revenue | 1.4% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-63.0M | — | ||
| Q2 25 | — | $-37.7M | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.5M | ||
| Q2 23 | — | $-31.9M |
| Q4 25 | $-63.4M | — | ||
| Q2 25 | — | $-37.8M | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 23 | — | $-31.9M |
| Q4 25 | -194.8% | — | ||
| Q2 25 | — | -197.2% | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 23 | — | -369.3% |
| Q4 25 | 1.4% | — | ||
| Q2 25 | — | 0.5% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 23 | — | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLOO
| Platform Solutions | $12.7M | 39% |
| Advertising | $11.1M | 34% |
| Marketplace | $3.9M | 12% |
| Midwestern Acquisition | $2.7M | 8% |
| Servant Acquisition | $1.8M | 6% |
NAMS
Segment breakdown not available.
